Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsMarcus Stark, Ulrike D Sent, Ingo Lang
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.
Claims12
A method of treating hypertension in a cat in need thereof, the method comprising daily administration of a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) or a pharmaceutically acceptable salt thereof to the cat, wherein the sartan is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan, and the therapeutically effective amount of the sartan is at least 0.75 mg/kg of body weight and not greater than 5.0 mg/kg of body weight.
A method of treating hypertension in a cat in need thereof, the method comprising daily administration of a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) or a pharmaceutically acceptable salt thereof to the cat, wherein the sartan is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan, and the therapeutically effective amount of the sartan is at least 0.75 mg/kg of body weight and not greater than 5.0 mg/kg of body weight.
Dependencies are inferred from the claim text.